A prospective randomized 14-year follow-up study of bioactive glass and autogenous bone as bone graft substitutes in benign bone tumors.

A prospective randomized long-term follow-up study of bioactive glass (BG)-S53P4 and autogenous bone (AB) used as bone graft substitutes in benign bone tumor surgery during 1993-1997 was conducted. Twenty-one patients (11 in the BG group, 10 in the AB group) participated in a 14-year follow-up. X-rays and MRI scans were obtained, and in the BG group, CT scans were also performed. In the BG group, the filled cavity had a dense appearance on X-ray. MRI showed a mainly or partly fatty bone marrow, and in the large bone tumor group, remnants of glass granules were also observed. Increased cortical thickness was seen in nonossifying fibromas and enchondromas. BG-S53P4 is a safe and well-tolerated bone substitute with good long-term results. BG-S53P4 does not disturb the growth of bone in children. (c) 2010 Wiley Periodicals, Inc.

RCT Entities:   Population Interventions Outcomes